Albertsons Companies, Inc. 8-K

What Happened
Albertsons Companies, Inc. filed an 8‑K on April 14, 2026 announcing its financial results for the 13- and 53-week periods ended February 28, 2026, and disclosing a settlement framework to resolve substantially all opioid-related claims. Under the framework the company agreed to pay approximately $774 million over nine years (first payment expected April 30, 2026 into escrow). Albertsons recorded a related loss of approximately $774 million ($600 million net of tax) in its fourth quarter of fiscal 2025. Also, the Board increased the quarterly cash dividend 13% from $0.15 to $0.17 per common share, payable May 8, 2026 (record date April 24, 2026).

Key Details

• Opioid Settlement Framework: ~ $774 million total payable over nine years; estimated after-tax net present value ≈ $482 million.
• Charge recorded: ~$774 million loss recognized in Q4 fiscal 2025 ( ~$600 million net of tax). This GAAP charge does not affect the company’s Adjusted EBITDA or Adjusted net income, which exclude such settlement charges.
• Timing & contingencies: First payment expected April 30, 2026 into escrow; framework is subject to participation by states, political subdivisions and tribes and other contingencies; company retains discretion on effectiveness.
• Dividend: Quarterly cash dividend increased from $0.15 to $0.17 (13%); payable May 8, 2026 to holders of record at close of business April 24, 2026.

Why It Matters
The $774M settlement framework and the one-time charge materially affect GAAP results for the most recent quarter (reducing reported net income), but management’s adjusted metrics exclude the settlement charge—so investors should compare both GAAP and adjusted figures. The multi-year payment schedule limits near-term cash outflows relative to a lump-sum payment, but still represents a meaningful long-term liability and affects the company’s liability profile (NPV ~ $482M). The dividend increase signals the board’s willingness to return cash to shareholders despite the settlement exposure. Finally, the settlement is contingent on participation levels, so outcomes could change until the framework becomes effective.